Federica Polato1, Paolo Rusconi, Stefano Zangrossi, Federica Morelli, Mattia Boeri, Alberto Musi, Sergio Marchini, Vittoria Castiglioni, Eugenio Scanziani, Valter Torri, Massimo Broggini. 1. Affiliations of authors: Laboratory of Molecular Pharmacology (FP, PR, SZ, FM, MBo, AM, SM, MBr), and Laboratory of Methodology for Biomedical Research (VT), Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Dipartimento di Patologia Animale, Igiene e Sanità Pubblica Veterinaria, Università degli Studi di Milano, Milan, Italy (VC, ES); Mouse and Animal Pathology Laboratory, Fondazione Filarete, Milan, Italy (VC, ES); Present address: Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD (FP).
Abstract
BACKGROUND: p53 influences genomic stability, apoptosis, autophagy, response to stress, and DNA damage. New p53-target genes could elucidate mechanisms through which p53 controls cell integrity and response to damage. METHODS: DRAGO (drug-activated gene overexpressed, KIAA0247) was characterized by bioinformatics methods as well as by real-time polymerase chain reaction, chromatin immunoprecipitation and luciferase assays, time-lapse microscopy, and cell viability assays. Transgenic mice (94 p53(-/-) and 107 p53(+/-) mice on a C57BL/6J background) were used to assess DRAGO activity in vivo. Survival analyses were performed using Kaplan-Meier curves and the Mantel-Haenszel test. All statistical tests were two-sided. RESULTS: We identified DRAGO as a new p53-responsive gene induced upon treatment with DNA-damaging agents. DRAGO is highly conserved, and its ectopic overexpression resulted in growth suppression and cell death. DRAGO(-/-) mice are viable without macroscopic alterations. However, in p53(-/-) or p53(+/-) mice, the deletion of both DRAGO alleles statistically significantly accelerated tumor development and shortened lifespan compared with p53(-/-) or p53(+/-) mice bearing wild-type DRAGO alleles (p53(-/-), DRAGO(-/-) mice: hazard ratio [HR] = 3.25, 95% confidence interval [CI] = 1.7 to 6.1, P < .001; p53(+/-), DRAGO(-/-) mice: HR = 2.35, 95% CI = 1.3 to 4.0, P < .001; both groups compared with DRAGO(+/+) counterparts). DRAGO mRNA levels were statistically significantly reduced in advanced-stage, compared with early-stage, ovarian tumors, but no mutations were found in several human tumors. We show that DRAGO expression is regulated both at transcriptional-through p53 (and p73) and methylation-dependent control-and post-transcriptional levels by miRNAs. CONCLUSIONS: DRAGO represents a new p53-dependent gene highly regulated in human cells and whose expression cooperates with p53 in tumor suppressor functions.
BACKGROUND:p53 influences genomic stability, apoptosis, autophagy, response to stress, and DNA damage. New p53-target genes could elucidate mechanisms through which p53 controls cell integrity and response to damage. METHODS:DRAGO (drug-activated gene overexpressed, KIAA0247) was characterized by bioinformatics methods as well as by real-time polymerase chain reaction, chromatin immunoprecipitation and luciferase assays, time-lapse microscopy, and cell viability assays. Transgenic mice (94 p53(-/-) and 107 p53(+/-) mice on a C57BL/6J background) were used to assess DRAGO activity in vivo. Survival analyses were performed using Kaplan-Meier curves and the Mantel-Haenszel test. All statistical tests were two-sided. RESULTS: We identified DRAGO as a new p53-responsive gene induced upon treatment with DNA-damaging agents. DRAGO is highly conserved, and its ectopic overexpression resulted in growth suppression and cell death. DRAGO(-/-) mice are viable without macroscopic alterations. However, in p53(-/-) or p53(+/-) mice, the deletion of both DRAGO alleles statistically significantly accelerated tumor development and shortened lifespan compared with p53(-/-) or p53(+/-) mice bearing wild-type DRAGO alleles (p53(-/-), DRAGO(-/-) mice: hazard ratio [HR] = 3.25, 95% confidence interval [CI] = 1.7 to 6.1, P < .001; p53(+/-), DRAGO(-/-) mice: HR = 2.35, 95% CI = 1.3 to 4.0, P < .001; both groups compared with DRAGO(+/+) counterparts). DRAGO mRNA levels were statistically significantly reduced in advanced-stage, compared with early-stage, ovarian tumors, but no mutations were found in several humantumors. We show that DRAGO expression is regulated both at transcriptional-through p53 (and p73) and methylation-dependent control-and post-transcriptional levels by miRNAs. CONCLUSIONS:DRAGO represents a new p53-dependent gene highly regulated in human cells and whose expression cooperates with p53 in tumor suppressor functions.
Authors: A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: Liudmila L Kodach; Rutger J Jacobs; Jarom Heijmans; Carel J M van Noesel; Alexandra M J Langers; Hein W Verspaget; Daniel W Hommes; G Johan A Offerhaus; Gijs R van den Brink; James C H Hardwick Journal: Carcinogenesis Date: 2010-07-14 Impact factor: 4.944
Authors: Aikaterini F Giannopoulou; Eumorphia G Konstantakou; Athanassios D Velentzas; Socratis N Avgeris; Margaritis Avgeris; Nikos C Papandreou; Ilianna Zoi; Vicky Filippa; Stamatia Katarachia; Antonis D Lampidonis; Anastasia Prombona; Popi Syntichaki; Christina Piperi; Efthimia K Basdra; Vassiliki Iconomidou; Evangelia Papadavid; Ema Anastasiadou; Issidora S Papassideri; Athanasios G Papavassiliou; Gerassimos E Voutsinas; Andreas Scorilas; Dimitrios J Stravopodis Journal: Int J Mol Sci Date: 2019-02-21 Impact factor: 5.923
Authors: Joseph L Regan; Dirk Schumacher; Stephanie Staudte; Andreas Steffen; Ralf Lesche; Joern Toedling; Thibaud Jourdan; Johannes Haybaeck; Dominik Mumberg; David Henderson; Balázs Győrffy; Christian R A Regenbrecht; Ulrich Keilholz; Reinhold Schäfer; Martin Lange Journal: iScience Date: 2021-05-24